These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7271272)

  • 21. Kinetics of netilmicin and gentamicin.
    Jahre JA; Fu KP; Neu HC
    Clin Pharmacol Ther; 1978 May; 23(5):591-7. PubMed ID: 639434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological variability of multiple dose pharmacokinetics of netilmicin in man.
    Blaser J; Rieder H; Niederer P; Lüthy R
    Eur J Clin Pharmacol; 1983; 24(3):399-406. PubMed ID: 6861854
    [No Abstract]   [Full Text] [Related]  

  • 23. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis.
    Bauer LA; Piecoro JJ; Wilson HD; Blouin RA
    Clin Pharm; 1983; 2(3):262-4. PubMed ID: 6883955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Netilmicin and gentamicin multidose kinetics in normal subjects.
    Laskin OL; Longstreth JA; Smith CR; Lietman PS
    Clin Pharmacol Ther; 1983 Nov; 34(5):644-50. PubMed ID: 6627825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of azlocillin in children with and without cystic fibrosis treated for infectious diseases.
    Michalsen H; Bergan T
    Methods Find Exp Clin Pharmacol; 1986 Dec; 8(12):727-9. PubMed ID: 3807473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Netilmicin: clinical pharmacokinetics and aspects on dosage schedules. An overview.
    Kahlmeter G
    Scand J Infect Dis Suppl; 1980; Suppl 23():74-81. PubMed ID: 7010548
    [No Abstract]   [Full Text] [Related]  

  • 27. Altered prednisolone pharmacokinetics in patients with cystic fibrosis.
    Dove AM; Szefler SJ; Hill MR; Jusko WJ; Larsen GL; Accurso FJ
    J Pediatr; 1992 May; 120(5):789-94. PubMed ID: 1578318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal clearance of gentamicin in cystic fibrosis.
    MacDonald NE; Anas NG; Peterson RG; Schwartz RH; Brooks JG; Powell KR
    J Pediatr; 1983 Dec; 103(6):985-90. PubMed ID: 6644440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical pharmacology of netilmicin in preterm and term newborn infants.
    Granati B; Assael BM; Chung M; Montini C; Parini R; Pollazzon P; Gagliardi L; Radwanski E; Rubaltelli FF
    J Pediatr; 1985 Apr; 106(4):664-9. PubMed ID: 3981323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance.
    Lanng S; Thorsteinsson B; Røder ME; Nerup J; Koch C
    Clin Endocrinol (Oxf); 1994 Aug; 41(2):217-23. PubMed ID: 7923827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extravascular penetration of tobramycin and netilmicin in a subcutaneous visking chamber model in rabbits.
    Larson TA; Gerding DN; Peterson LR
    Antimicrob Agents Chemother; 1983 Oct; 24(4):594-6. PubMed ID: 6651282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacolinetic study of netilmicin in children].
    Valeteau de Moulliac J; Lordier A; Coignard S; Gallet JP
    Arch Fr Pediatr; 1982 Jan; 39(1):57. PubMed ID: 7065824
    [No Abstract]   [Full Text] [Related]  

  • 33. Cloxacillin absorption and disposition in cystic fibrosis.
    Spino M; Chai RP; Isles AF; Thiessen JJ; Tesoro A; Gold R; MacLeod SM
    J Pediatr; 1984 Nov; 105(5):829-35. PubMed ID: 6502318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.
    LeBel M; Bergeron MG; Vallée F; Fiset C; Chassé G; Bigonesse P; Rivard G
    Antimicrob Agents Chemother; 1986 Aug; 30(2):260-6. PubMed ID: 3094438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Netilmicin use in pediatric patients.
    Chindasilpa V; Schauf V; Hamilton LR; Riff LJ
    Dev Pharmacol Ther; 1980; 1(4):238-53. PubMed ID: 7438970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Netilmicin pharmacokinetics in uremic patients undergoing hemodialysis.
    Scatizzi A; Basile C; Strippoli P; Di Maggio A; Orbello G; Lodeserto C; Triarico A; Mingrone G; Longo S; Curino E
    Chemioterapia; 1986 Oct; 5(5):327-9. PubMed ID: 3791480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
    Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
    Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cephalexin pharmacokinetics in patients with cystic fibrosis.
    Nahata MC; Lubin AH; Visconti JA
    Dev Pharmacol Ther; 1984; 7(4):221-8. PubMed ID: 6468223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftazidime disposition in acute and stable cystic fibrosis.
    Leeder JS; Spino M; Isles AF; Tesoro AM; Gold R; MacLeod SM
    Clin Pharmacol Ther; 1984 Sep; 36(3):355-62. PubMed ID: 6432400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic evaluation of cefsulodin in children with and without cystic fibrosis treated for infectious diseases.
    Michalsen H; Bergan T; Solberg R
    Methods Find Exp Clin Pharmacol; 1986 Nov; 8(11):685-7. PubMed ID: 3807469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.